Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours

BACKGROUND: Resistance to BRAF inhibition is a major cause of treatment failure for BRAF-mutated metastatic melanoma patients. Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, overcomes this resistance in xenograft tumours and offers a promising drug combination. The present work aims to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Tate, Sonya C, Burke, Teresa F, Hartman, Daisy, Kulanthaivel, Palaniappan, Beckmann, Richard P, Cronier, Damien M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800303/
https://www.ncbi.nlm.nih.gov/pubmed/26978007
http://dx.doi.org/10.1038/bjc.2016.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800303/
https://www.ncbi.nlm.nih.gov/pubmed/26978007
http://dx.doi.org/10.1038/bjc.2016.40

Ejemplares similares